

Accepted Manuscript

Title: Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program

Author: Michał Mazurek, Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Kristina Zint, Lionel Riou França, Shihai Lu, Gregory Y.H. Lip, GLORIA-AF Investigators

PII: S0002-9343(18)30305-X
DOI: <https://doi.org/10.1016/j.amjmed.2018.03.024>
Reference: AJM 14608

To appear in: *The American Journal of Medicine*



Please cite this article as: Michał Mazurek, Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Kristina Zint, Lionel Riou França, Shihai Lu, Gregory Y.H. Lip, GLORIA-AF Investigators, Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program, *The American Journal of Medicine* (2018), <https://doi.org/10.1016/j.amjmed.2018.03.024>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Gender Differences in Antithrombotic Treatment For Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program

Michał Mazurek MD, PhD,^{a,b} Menno V. Huisman MD, PhD,^c Kenneth J. Rothman DrPH,^d Miney Paquette MSc,^e Christine Teutsch MD,^f Hans-Christoph Diener MD, PhD,^g Sergio J. Dubner MD,^h Jonathan L. Halperin MD,ⁱ Kristina Zint PhD,^j Lionel Riou França PhD,^j Shihai Lu PhD,^k Gregory Y.H. Lip MD,^{a,l,*} on behalf of the GLORIA-AF Investigators

From the ^aInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; ^bDepartment of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Medical University, Silesian Centre for Heart Diseases, Zabrze, Poland; ^cDepartment of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands; ^dRTI Health Solutions, Research Triangle Institute, Research Triangle Park, North Carolina; ^eDepartment of Medicine, Boehringer Ingelheim, Burlington, Canada; ^fDepartment of Clinical Development and Medical Affairs, Boehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, Germany; ^gDepartment of Neurology, University of Duisburg-Essen, Germany; ^hClínica y Maternidad Suizo Argentina, Buenos Aires, Argentina; ⁱIcahn School of Medicine at Mount Sinai, New York, New York; ^jGlobal Epidemiology Department, Boehringer Ingelheim, Ingelheim, Germany; ^kBiostatistics and Data Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States of America; ^lAalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Running head: Gender-related anticoagulation in atrial fibrillation

*Corresponding Author

Professor GYH Lip

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

Tel: +44 121 507 5080; E-mail: g.y.h.lip@bham.ac.uk

Clinical Trial Registration: <http://www.clinicaltrials.gov>. Unique identifier: NCT01468701

Authorship: All authors had access to the data and played a role in writing this manuscript.

Download English Version:

<https://daneshyari.com/en/article/8944090>

Download Persian Version:

<https://daneshyari.com/article/8944090>

[Daneshyari.com](https://daneshyari.com)